Literature DB >> 8324857

High prevalence of mefloquine-resistant falciparum malaria in eastern Thailand.

A L Fontanet1, D B Johnston, A M Walker, W Rooney, K Thimasarn, D Sturchler, M Macdonald, M Hours, D F Wirth.   

Abstract

In order to assess the risk and predictors of mefloquine resistance we monitored a cohort of 113 patients in eastern Thailand who had been treated for uncomplicated falciparum malaria with a single dose of 15 mg/kg of the drug and followed up for 42 days. The overall treatment failure rate at day 42 was 59.1% (95% confidence interval (CI) = 50%, 68%) with only 2.7% of the patients being lost to follow-up. There were 6.4% RIII, 20.9% RII, 31.8% RI, and 40.9% sensitive responses, based on a modified WHO classification. A low haemoglobin level on the day of treatment and diarrhoea during the first two days after treatment were independent predictors of treatment failure. These findings remained statistically significant in a Cox proportional hazards model, after controlling for other baseline characteristics and adverse effects. Although a history of digestive disorders prior to treatment was associated with diarrhoea on day 2 (P = 0.024), it was in itself not a predictor of treatment failure (adjusted hazard ratio = 1.16; 95% CI = 0.35, 2.14). A total of 60 patients with an R response were hospitalized for 7 days to receive supervised treatment with quinine-tetracycline. Only three had a positive thick smear for asexual forms of Plasmodium falciparum 14 days later, and quinine-tetracycline therefore remains a good alternative treatment for mefloquine-resistant falciparum malaria.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8324857      PMCID: PMC2393499     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  11 in total

1.  In vitro and clinical correlates of mefloquine resistance of Plasmodium falciparum in eastern Thailand.

Authors:  G E Childs; E F Bourdeau; T Wimonwattratee; L Pang; W K Milhous
Journal:  Am J Trop Med Hyg       Date:  1991-05       Impact factor: 2.345

2.  Treatment of falciparum malaria with quinne and tetracycline or combined mefloquine/sulfadoxine/pyrimethamine on the Thai-Kampuchean border.

Authors:  S R Meek; E B Doberstyn; B A Gaüzère; C Thanapanich; E Nordlander; S Phuphaisan
Journal:  Am J Trop Med Hyg       Date:  1986-03       Impact factor: 2.345

Review 3.  The problem of drug resistance in malaria.

Authors:  W Peters
Journal:  Parasitology       Date:  1985-04       Impact factor: 3.234

4.  The current situation of the anti-malaria programme in Thailand.

Authors:  S Malikul
Journal:  Southeast Asian J Trop Med Public Health       Date:  1988-09       Impact factor: 0.267

5.  Mefloquine kinetics in cured and recrudescent patients with acute falciparum malaria and in healthy volunteers.

Authors:  E F Boudreau; L Fleckenstein; L W Pang; G E Childs; A C Schroeder; B Ratnaratorn; P Phintuyothin
Journal:  Clin Pharmacol Ther       Date:  1990-10       Impact factor: 6.875

6.  Mefloquine-resistant falciparum malaria on the Thai-Burmese border.

Authors:  F Nosten; F ter Kuile; T Chongsuphajaisiddhi; C Luxemburger; H K Webster; M Edstein; L Phaipun; K L Thew; N J White
Journal:  Lancet       Date:  1991-05-11       Impact factor: 79.321

7.  Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of age in Malawi: in vivo/in vitro efficacy and correlation of drug concentration with parasitological outcome.

Authors:  L M Slutsker; C O Khoromana; D Payne; C R Allen; J J Wirima; D L Heymann; L Patchen; R W Steketee
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

8.  Single-dose therapy of falciparum malaria with mefloquine or pyrimethamine-sulfadoxine.

Authors:  E B Doberstyn; P Phintuyothin; S Noeypatimanondh; C Teerakiartkamjorn
Journal:  Bull World Health Organ       Date:  1979       Impact factor: 9.408

9.  The antimalarial drug mefloquine binds to membrane phospholipids.

Authors:  R Chevli; C D Fitch
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

10.  A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand.

Authors:  T Harinasuta; D Bunnag; W H Wernsdorfer
Journal:  Bull World Health Organ       Date:  1983       Impact factor: 9.408

View more
  9 in total

1.  Antimalarial activity of the bisquinoline trans-N1,N2-bis (7-chloroquinolin-4-yl)cyclohexane-1,2-diamine: comparison of two stereoisomers and detailed evaluation of the S,S enantiomer, Ro 47-7737.

Authors:  R G Ridley; H Matile; C Jaquet; A Dorn; W Hofheinz; W Leupin; R Masciadri; F P Theil; W F Richter; M A Girometta; A Guenzi; H Urwyler; E Gocke; J M Potthast; M Csato; A Thomas; W Peters
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

Review 2.  New antimalarials. A risk-benefit analysis.

Authors:  F Nosten; R N Price
Journal:  Drug Saf       Date:  1995-04       Impact factor: 5.606

3.  4-aminoquinoline analogs of chloroquine with shortened side chains retain activity against chloroquine-resistant Plasmodium falciparum.

Authors:  R G Ridley; W Hofheinz; H Matile; C Jaquet; A Dorn; R Masciadri; S Jolidon; W F Richter; A Guenzi; M A Girometta; H Urwyler; W Huber; S Thaithong; W Peters
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 4.  Antimalarial drug resistance: a review of the biology and strategies to delay emergence and spread.

Authors:  E Y Klein
Journal:  Int J Antimicrob Agents       Date:  2013-02-08       Impact factor: 5.283

5.  Falciparum malaria in eastern Thailand: a randomized trial of the efficacy of a single dose of mefloquine.

Authors:  A L Fontanet; B D Johnston; A M Walker; Y Bergqvist; U Hellgren; W Rooney
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

6.  Deployment of early diagnosis and mefloquine-artesunate treatment of falciparum malaria in Thailand: the Tak Malaria Initiative.

Authors:  Verena Ilona Carrara; Supakit Sirilak; Janjira Thonglairuam; Chaiporn Rojanawatsirivet; Stephane Proux; Valery Gilbos; Al Brockman; Elizabeth A Ashley; Rose McGready; Srivicha Krudsood; Somjai Leemingsawat; Sornchai Looareesuwan; Pratap Singhasivanon; Nicholas White; François Nosten
Journal:  PLoS Med       Date:  2006-06       Impact factor: 11.069

7.  Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial.

Authors:  Sodiomon B Sirima; Bernhards Ogutu; John P A Lusingu; Ali Mtoro; Zakayo Mrango; Alphonse Ouedraogo; Jean Baptiste Yaro; Kevin Omondi Onyango; Samwel Gesase; Ernest Mnkande; James Samwel Ngocho; Isabelle Ackermann; François Aubin; Joelle Vanraes; Nathalie Strub; Gwenaelle Carn
Journal:  Lancet Infect Dis       Date:  2016-07-16       Impact factor: 25.071

8.  In vitro susceptibility of Indian Plasmodium falciparum isolates to different antimalarial drugs & antibiotics.

Authors:  Pooja Agarwal; A R Anvikar; C R Pillai; Kumkum Srivastava
Journal:  Indian J Med Res       Date:  2017-11       Impact factor: 2.375

9.  Four years' monitoring of in vitro sensitivity and candidate molecular markers of resistance of Plasmodium falciparum to artesunate-mefloquine combination in the Thai-Myanmar border.

Authors:  Papichaya Phompradit; Poonuch Muhamad; Raewadee Wisedpanichkij; Wanna Chaijaroenkul; Kesara Na-Bangchang
Journal:  Malar J       Date:  2014-01-15       Impact factor: 2.979

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.